Infertility Clinical Trial
Official title:
Effect of Endometrial Injury Before Frozen Embryo Transfer on Pregnancy Rate
Research Question:
In women undergoing frozen embryo transfer, does routine endometrial injury before frozen
embryo transfer increase clinical pregnancy rate?
Research Hypothesis:
(Null Hypothesis) In women undergoing frozen embryo transfer Routine endometrial injury
before frozen embryo transfer does not increase clinical pregnancy rate.
(Alternative Hypothesis) In women undergoing frozen embryo transfer, endometrial injury
before the transfer may increase pregnancy rate.
Suitable women will be invited to participate in the study then a signed and informed consent
will be obtained from them. When the patient's consent is obtained, they are to be included
into the study.
Data Collection:
During first visit, all patients will undergo complete clinical examination and detailed
medical history will be obtained. Each patient will have a Case Record Form (CRF) in which
the following data will be recorded.
- Patient number (according to the randomization schedule).
- Age, BMI.
- Past medical and surgical history.
- Duration of infertility.
Procedure:
Endometrial injury:
A single induced injury will be done on the posterior endometrium on day 7 of the transfer
cycle by using modified Cook catheter Protocol for vitrification Embryos will first loaded
with equilibrium solution containing7.5% ethylene glycol (EG) and 7.5% dimethyl sulphoxide
(DSMO) (Sigma-Aldrich) for 5-10 minute at room temperature and then with vitrification
solution containing 15% EG, 15% DSMO and 0.5 mol/L sucrose for 50-60 seconds at room
temperature. After observed cellular shrinkage, embryos will quickly stored in liquid
nitrogen (LN) for at least 2 months. At warming, embryos will removed from LN and embryos
will exposed to thawing solution containing sucrose at 37°C temperature for 50-60 seconds and
then embryos will sequentially incubated in diluents solutions before being transferred .
Evaluation and transfer of thawed embryos After thawing, each embryo will evaluated twice,
once immediately for the number of surviving blastomeres and again after 18 hours post-thaw
in vitro culture for assessing of mitosis and number of blastomeres. Embryos will considered
survived if >50% of each blastomere are intact and selected for intrauterine transfer
(Depending on patients' embryos, 2 or 3 embryos will transferred).
Embryos will classified as fully intact or excellent morphology (100% cells survived with
<10% fragmentation) or good morphology (100% cells survived with 10%-20% fragmentation),
partially damaged or poor morphology (≥50% cells survived with or without any fragmentation)
and Degenerated embryos (<50% cells survived) .Only fully intact and partially damaged
embryos will transferred. Degenerated or arrested embryos will not transferred.
Protocol of endometrial preparation before Frozen Embryo Transfer (FET) :
There are different protocols for FET cycles. That is true for both "natural cycle" FETs and
for "hormone replacement cycle" frozen-thawed embryo transfers. We will use hormone
replacement cycles because they have better success rates. However, some clinics offer a
natural cycle FET approach. Success rates are higher with hormone replacement, or
"controlled" FET cycles.
Medicines and Drugs in a Frozen Embryo Transfer FET Cycle
1. Gonadotropin-Releasing Hormone agonist (such as Lupron) will be given, either midluteal
(day 21) or overlapping with a birth control pill.
2. Down-regulation will be confirmed by ultrasound and blood tests.
3. Estradiol valerate 2 mg twice daily (orally) will start after the period. This dose may
need to be increased after monitoring of the uterine lining thickness.
4. When the endometrium has a "good" thickness( > 8 mm), progesterone will be started
(intramuscular shots, or a vaginal product).
5. Embryo transfer will be planned for 3-6 days later - depending on the stage of
development of the embryos to be transferred.
6. Estrogen and progesterone will be continued in the luteal phase.
7. Pregnancy testing will be done 9-14 days after transfer - depending on the stage of
development of the embryos replaced and the preferences of the fertility clinic.
8. If pregnant, estrogen and progesterone will be continued until about 10-15 weeks of
pregnancy and then weaned off.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
| Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
| Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
| Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
| Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
| Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
| Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
| Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
| Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
| Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
| Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
| Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
| Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
| Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
| Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
| Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
| Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
| Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
| Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
| Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A |